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ABSTRACT
Objectives Previous studies of women in their 20s and 
30s have reported impaired autonomic function in women 
with polycystic ovary syndrome (PCOS). We aimed to 
study, for the first time, whether PCOS is associated with 
impaired cardiac autonomic function independent of 
metabolic and hormonal status in their late reproductive 
years.
Design A prospective Northern Finland Birth Cohort 
1966 (NFBC1966) study including 5889 women born 
in 1966 and followed through the age of 46. At that 
age, n=3706/5123 women (72%) answered the postal 
questionnaires and n=3280/5123 women (64%) 
participated in the clinical examination.
Setting General community.
Participants The sample included women presenting 
both irregular menses (oligomenorrhoea or amenorrhoea) 
and hirsutism at age 31 (n=125) or with formally 
diagnosed PCOS by age 46 (n=181) and women without 
PCOS symptoms or diagnosis (n=1577).
Primary and secondary outcome measures Heart rate 
variability parameters: the root mean square of successive 
R- R differences (rMSSD), spectral power densities (LF: 
low frequency and HF: high frequency) and baroreflex 
sensitivity (BRS).
Results We found that parasympathetic activity 
(assessed by rMSSD: 19.5 (12.4; 31.9) vs 24.3 (16.1; 
34.8) ms, p=0.004 and HF: 172 (75; 399) vs 261 
(112; 565) ms2, p=0.002) and BRS (6.13±3.12 vs 
6.99±3.52 ms/mm Hg, p=0.036) were lower in women 
with PCOS compared with the controls. However, in the 
multivariate regression analysis, PCOS, body mass index 
and the free androgen index did not significantly associate 
with rMSSD, whereas blood pressure, insulin resistance 
and triglycerides did.
Conclusions We report here for the first time that late 
reproductive- aged women with PCOS display impaired 
cardiac autonomic function manifested as decreased vagal 
activity. Metabolic status, rather than hyperandrogenaemia 
and PCOS per se, was the strongest contributing factor. 
Given the link between cardiac morbidity and impaired 
autonomic function, the findings underline the importance 
of screening and treating metabolic abnormalities early on 
in women with PCOS.
InTRODuCTIOn
Polycystic ovary syndrome (PCOS) is the 
most common endocrinopathy, affecting 
6%–18% of women of reproductive age and 
characterised by irregular menstruation, clin-
ical or biochemical hyperandrogenism and 
polycystic ovaries.1–3 Women with PCOS are 
commonly overweight or obese and typically 
present with insulin resistance, hyperinsu-
linaemia, increased blood pressure (BP), 
dyslipidaemia, metabolic syndrome and 
obstructive sleep apnoea,2 all of which are 
associated with impaired cardiac autonomic 
function.4–6 In the general population, the 
dysregulation of cardiac autonomic function 
has been associated with increased risk of 
many major global public health problems, 
such as depression,7 anxiety,8 hypertension, 
diabetes, cardiovascular diseases (CVDs) 
and mortality.9 Therefore, it is not surprising 
that women with PCOS have been shown to 
present with impaired cardiac autonomic 
function, that is, reduced parasympathetic 
(vagal) activity,10–12 and increased sympa-
thetic nervous system activity.13 14 Previous 
researchers have used various methods, such 
as microneurography, the measurement of 
sympathetic skin responses, heart rate (HR) 
Strengths and limitations of this study
 ► This is the first study to investigate the cardiac au-
tonomic function of late reproductive- aged women 
with polycystic ovary syndrome (PCOS). 
 ►  This study provides the largest study population by 
far compared with the previous studies in cardiac 
autonomic function in women with PCOS. 
 ►  We were able to adjust for many confounding factors 
and to study the effect of metabolic abnormalities. 
 ►  The study is limited by the lack of PCOS phenotypes. 
 ►  The study cannot be generalised with all ethnicities. copyright.
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variability (HRV), HR recovery and a norepinephrine 
spill- over measurement, to assess the cardiac autonomic 
function in women with PCOS. Of these methods, the 
measurement of HRV (ie, variations in the time inter-
vals between consecutive heartbeats) provides a well- 
established non- invasive method to assess, in particular, 
parasympathetic cardiac autonomic activity.15
During recent years, it has become an enigma whether 
women with PCOS have an increased risk for CVD. Taking 
into consideration that many PCOS traits, such as irregular 
cycles, hyperandrogenism and body mass index (BMI) 
difference from non- PCOS controls, seem to diminish 
with age,16 it is also important to assess CVD- related traits, 
such as cardiac autonomic function, in women with PCOS 
in the late reproductive years and beyond menopause to 
elucidate their possible risk for CVD outcomes. Previous 
studies on cardiac autonomic function have included 
women with PCOS in their 20s or 30s, but to date, no 
studies have been carried out on women in their late 
reproductive years. Moreover, the populations studied 
have been derived from PCOS clinics; thus, community- 
based studies are needed. Therefore, the main aim of 
this study was to investigate whether women with PCOS 
from a general population display reduced HRV as an 
indicator of impaired cardiac autonomic function during 
their late reproductive years (at age 46). Additionally, we 
investigated the role of confounding metabolic abnor-
malities, such as excess weight, abdominal obesity, hyper-
androgenism, increased BP, dyslipidaemia and insulin 
resistance, in the cardiac autonomic function in affected 
women.
MATeRIAlS AnD MeThODS
Study population
The study population comprises the Northern Finland 
Birth Cohort 1966 (NFBC1966), which is a large, prospec-
tive, general population- based, longitudinal birth cohort. 
All individuals with expected births during 1966 in the 
two northernmost provinces in Finland (Oulu and 
Lapland) were included in this birth cohort (12 231 
births, 5889 women, 96.3% of all births during 1966 in 
that area). Enrolment in this database began at the 24th 
gestational week, and the women were followed through 
age 46. The follow- up protocol of the cohort was previ-
ously described in detail, and the main data collection 
points during adulthood were carried out at ages 31 
and 46.17 Briefly, postal questionnaires were sent to all 
living cohort members with known addresses at ages 31 
(81% answered, n=4523/5608) and 46 (72% answered, 
n=3706/5123) to collect information about health, 
behaviour and social background. Postal questionnaires 
included an invitation to participate in clinical examina-
tions at ages 31 (77% participation rate, n=3127/4074) 
and 46 (64% participation rate, n=3280/5123). Weight 
and height were self- reported at age 14 (with the help 
of the participants’ parents) and clinically measured at 
ages 31 and 46. BMI was calculated as the ratio of weight 
(kg) and height squared (m2). Besides anthropometric 
measurements, the clinical examinations at age 46 
included blood sampling and assessments of cardiovas-
cular health status, including systolic and diastolic BP 
(SBP and DBP, respectively), carotid and cardiac ultra-
sound and evaluations of HRV and baroreflex sensitivity 
(BRS). Waist circumference was measured at the level 
midway between the lowest rib margin and the iliac crest. 
Brachial SBP and DBP were measured three times with 
1 min interval after 15 min rest by an automated, oscillo-
metric BP device with an appropriately sized cuff (Omron 
Digital Automatic Blood Pressure Monitor Model M10- IT; 
Omron, Kyoto, Japan), and SBP and DBP averages were 
calculated.18 The level of glucose metabolism was classi-
fied according to WHO standards,19 based on a 2- hour 
oral glucose tolerance test (performed at age 46) and a 
previously established diagnosis of type 2 diabetes.20
Definition of PCOS and control groups
At age 31, PCOS symptoms (ie, oligomenorrhoea/amen-
orrhoea and hirsutism) were self- reported. Of all the 
women who responded to questions regarding PCOS 
symptoms (n=4523), after excluding pregnant women 
and those using hormonal preparations (n=1459) or not 
permitting the use of their data (n=41), 4.1% (n=125) 
reported both oligomenorrhoea/amenorrheoa and 
hirsutism. The validity of this questionnaire to distin-
guish PCOS cases with typical hormonal, metabolic and 
psychological traits characteristic to the syndrome, as 
well as ovarian morphology for PCOS, has previously 
been described.20–23 At age 46, the postal questionnaire 
included a question on existing PCOS diagnosis, to which 
181 subjects responded ‘yes’. Consequently, the women 
reporting both oligomenorrhoea/amenorrhoea and 
hirsutism and/or reporting PCOS diagnosis by age 46 
were considered cases (n=279). Women without PCOS 
symptoms at age 31 and without diagnosis of PCOS by age 
46 were considered controls (n=1577). The characteris-
tics of the PCOS and control populations and the flow-
chart of the formation of the PCOS and control groups 
have previously been described.17
evaluation of cardiac autonomic function
A flowchart of the study is presented in figure 1. HRV was 
measured in the study subjects at age 46 in the research 
unit at Oulu University Hospital and in two other 
major hospitals nearby. The subjects were informed 
about the measurement protocol, and an HR monitor 
(RS800CX, Polar Electro Oy, Kempele, Finland) to 
record R- R intervals (RRi) and a standard lead- II ECG 
(Cardiolife, Nihon Kohden, Tokyo, Japan) were placed 
on the subjects while seated. Also, breathing frequency 
(MLT415/D, Nasal Temperature Probe, ADInstruments, 
Bella Vista, New South Wales, Australia) and BP by 
finger photoplethysmography (Nexfin, BMEYE Medical 
Systems, Amsterdam, the Netherlands) were recorded 
with a sampling frequency of 1000 Hz (PowerLab 8/35, 
ADInstruments). These preparations were followed by at 
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Figure 1 Flowchart of the study. HRV, heart rate variability; PCOS, polycystic ovary syndrome ; RRi, R- R interval.
least 1 min stabilisation period before the beginning of 
the 3 min recording period in the seated position. After 
that recording period, the participants stood up and 
remained still in a standing position for another 3 min 
while breathing normally.
Analysis of hRV
The first 150 s of recording in a seated position and the last 
150 s in a standing position were used in the analyses. The 
RRi data were edited based on visual inspections, and the 
artefacts and ectopic beats were removed and replaced 
according to the local average (Hearts 1.2, University of 
Oulu, Oulu, Finland). Sequences with ≥10 consecutive 
beats of noise or ectopic beats were deleted. The RRi 
series with ≥80% accepted data were included in the anal-
yses. The final study population included 1029 controls 
and 160 women with PCOS. Mean HR, rMSSD (the root 
mean square of successive R–R differences) and spectral 
power densities (fast Fourier transformation, length 512 
beats), including low frequency (LF: 0.04–0.15 Hz, ms2) 
and high frequency (HF: 0.15–0.40 Hz, ms2) components 
of HRV and their ratio (LF/HF), were analysed. While 
rMSSD and HF component of HRV are mainly deter-
mined by cardiac parasympathetic activity, LF component 
of HRV is affected largely by parasympathetic activity 
but also includes effects of sympathetic activity as well as 
other unidentified factors.15 24 The LF/HF ratio has been 
used as a marker of sympatho- vagal balance, particularly 
during orthostatic stimulus.25 However, as the physiolog-
ical background of LF component of HRV is complex, the 
conclusions concerning sympatho- vagal balance by LF/
HF are limited.24
Analysis of BRS
BRS was assessed in the participants who had the measures 
performed at the Oulu University Hospital (609 controls 
and 105 women with PCOS). Continuous ECG, BP and 
respiration signals were imported to custom- made, 
stand- alone Matlab- based software (Biosignal Processing 
Team, University of Oulu, Oulu, Finland), with which 
RRi and SBP values were extracted. Artefacts and ectopic 
beats were replaced using linear interpolation (<5% for 
accepted recording) and, thereafter, resampled at 2 Hz 
and detrended (<0.04 Hz, Savitzky–Golay method). A 
fast Fourier transform (Welch method, segments of 128 
samples with 50% overlap) was performed to analyse the 
LF (0.04–0.15 Hz) power of RRi and SBP oscillations for 
subsequent analysis of BRS using the alpha method if 
sufficient coherence (≥0.5) between LF oscillations in RRi 
and SBP was verified. The present BRS method quantifies 
cardiac autonomic responses to spontaneous SBP varia-
tion, detected by baroreceptors in the aortic arch and the 
carotid sinus, which include both parasympathetic and 
sympathetic effects.26 Concurrently, the LF oscillation of 
BP (LFSBP, 0.04–0.15 Hz) was obtained and considered as 
a surrogate for peripheral sympathetic activity. However, 
the physiological background of LFSBP is not fully estab-
lished, as there are competing theories of central oscilla-
tion of sympathetic drive and BRS resonance.27
laboratory methods
The laboratory methods have previously been described 
in detail.17 At age 46, sex hormone binding globulin 
(SHBG) was assayed by chemiluminometric immunoassay 
(Immulite 2000, Siemens Healthcare, Llanberis, UK). 
The serum samples for testosterone (T) were assayed 
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using Agilent triple quadrupole 6410 LC/MS equipment 
(Agilent Technologies, Wilmington, Delaware, USA). 
The free androgen index (FAI) was calculated using the 
following equation: (100×T)/SHBG. The serum total 
cholesterol, the high- density lipoprotein (HDL), the low- 
density lipoprotein (LDL) and triglycerides were deter-
mined using an enzymatic assay method. Fasting plasma 
glucose (f- gluc) was analysed by an enzymatic dehydro-
genase method (methods of cholesterol, HDL, LDL, 
triglycerides and f- gluc: Advia 1800, Siemens Healthcare 
Diagnostics, Tarrytown, New York, USA). Fasting serum 
insulin (f- ins) was analysed by a chemiluminometric 
immunoassay (Advia Centaur XP, Siemens Healthcare 
Diagnostics, Tarrytown, New York, USA). The f- gluc and 
f- ins values were used to calculate the Homeostasis Model 
Assessment–insulin resistance (HOMA- IR) index (f- gluc 
× f- ins/22.5). The high- sensitivity C- reactive protein 
(hsCRP) was analysed by an immune- nephelometric assay 
(BN ProSpec, Siemens Healthcare Diagnostics, Newark, 
Delaware, USA). The samples were analysed at NordLab 
Oulu, a testing laboratory (T113) accredited by the 
Finnish Accreditation Service (FINAS) (EN ISO 15189).
hopkins Symptom Check list-25
Hopkins Symptom Check List-25 Part 1 includes 10 items 
that check for anxiety symptoms, and this part was used 
in the present study.28
Statistical methods
Women using beta- blockers (104 controls (7.7%) and 
30 women with PCOS (13.3%), p=0.009) were excluded 
from the HRV analysis. Continuous data were presented 
as mean with SD or as median with 25% and 75% quar-
tiles. Continuous variables with skewed distributions were 
transformed into a natural logarithm (ln). Differences in 
normally distributed continuous parameters were anal-
ysed using the Student’s t-test, whereas the Mann–Whitney 
U- test was used in the case of skewed distribution. Cate-
gorical data were reported as prevalence with the number 
of cases, and the difference between the study groups was 
analysed by cross tabulation and the χ2 test or the Fisher’s 
exact test, when appropriate. The mean arterial pressure 
(MAP) was calculated as follows: DBP +  
1
3  (SBP – DBP).
Univariate and multivariate linear regression analyses 
were used to study the factors associated with the HRV 
parameters. First, univariate linear regression models 
were used to reveal the parameters that were signifi-
cantly associated with the outcome variable. Then, step-
wise multivariate models were used to identify the most 
important explanatory variables. The final multivariate 
model included the following variables as explanatory 
variables: PCOS, BMI at age 46, MAP, FAI, HOMA- IR 
and triglycerides. The number of explanatory variables 
included in the final model had to be limited to avoid 
multicollinearity. BMI was included in the model, as 
it significantly differs between the PCOS and control 
women, and obesity is suggested to affect HRV.4 MAP 
was selected because it combines information from both 
SBP and DBP; FAI was included in the model because it 
is considered a good indicator of hyperandrogenaemia 
in women with PCOS2 and hyperandrogenaemia has 
been suggested to alter HRV in women with PCOS.14 The 
homeostasis model assessment for insulin resistance was 
used as an estimate of insulin resistance, as it combines 
information from both fasting insulin and glucose levels, 
and triglycerides was included, as hypertriglyceridaemia 
is a typical lipid abnormality in PCOS women and is 
linked to CVD risks.29 Anxiety was not included in the 
final multivariate model, because in the preliminary 
models using the stepwise method it was always the first 
variable to be excluded. The results of linear regression 
models are reported as unstandardised coefficients (B), 
95% confidence intervals for B, p values and R2 values 
for the model. The multicollinearity assumptions of the 
multivariate linear regression model were investigated 
using variance inflation factor (VIF), tolerance and 
eigenvalue indexes. In addition, a histogram of regres-
sion standardised residual frequency, normal P–P plot of 
regression- standardised residuals and scatter plot figures 
were visually inspected to ensure that the model met the 
assumptions in the analysis. The data were analysed using 
SPSS software (IBM SPSS Statistics V.24.0, IBM Corp.). A 
p value<0.05 was considered statistically significant.
All the participants took part on a voluntary basis and 
signed informed consent forms.
Patient and public involvement statement
The patients, the public or any third parties were not 
involved in the design, conduct, reporting or dissemina-
tion of our research.
ReSulTS
hRV and BRS
When compared with the control women, the women 
with PCOS in a seated position had a significantly higher 
mean HR and significantly lower values of rMSSD, LFRRi, 
HFRRi and BRS (figure 2). However, when adjusting for 
BMI at age 46, the women with PCOS had lower values 
only in rMSSD (p=0.033) and HFRRi (p=0.016) compared 
with the controls. In the standing position, the women 
with PCOS did not differ from the controls after adjust-
ment for BMI at age 46 (data not shown).
hRV according to BMI group
After dividing the women according to BMI (<25 or≥25 kg/
m2), the lean women with PCOS did not differ from the 
lean control women regarding the HRV parameters, 
whereas the overweight/obese women with PCOS had 
higher HRs and lower rMSSD, LFRRi and HFRRi compared 
with the overweight/obese controls (figure 3). It is note-
worthy that the overweight/obese women with PCOS had 
higher BMIs and waist circumferences and had abnormal 
glucose metabolism and hyperandrogenaemia more 
often than the overweight/obese control women (data 
not shown).
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Figure 2 Heart rate variability parameters in controls and in women with PCOS at age 46 in seated position. The users of beta- 
blockers were excluded. Values are mean±SD or median with 25% and 75% quartiles, and the significance testing was made 
by Student’s t test (ln- transform was made to achieve normality). HR, heart rate; rMSSD, the root mean square of successive 
R–R differences; LFRRi, low- frequency (0.04–0.15 Hz) power; HFRRi, high- frequency (0.15–0.4 Hz) power; α1, short- term fractal- like 
scaling exponent by detrended fluctuation analysis; SBP, systolic blood pressure; BRS, baroreflex sensitivity; PCOS, polycystic 
ovary syndrome.
We also further divided the population into overweight 
(BMI 25–30 kg/m2) and obese (BMI >30 kg/m2) groups. 
We found that the overweight women with PCOS (n=55) 
had significantly lower rMSSD (2.54±0.6 vs 2.90±0.6, 
p=0.006), LFRRi (4.91±0.9 vs 5.52±0.9, p=0.034) and HFRRi 
(4.30±1.2 vs 5.00±1.2, p=0.010) compared with the over-
weight control women (n=328), whereas HR (80.0±11.2 
vs 75.8±9.6, p=0.064), LF/HF ratio (0.61±0.9 vs 0.51±0.9, 
p=0.187), LFSBP (1.51±0.8 vs 1.80±0.8, p=0.087), BRS 
(1.67±0.4 vs 1.81±0.5, p=0.182) and α (1.68±0.4 vs 
1.81±0.5, p=0.182) did not differ between these two 
groups. We found no significant differences between the 
obese PCOS and control women in any HRV parameters, 
but this might be due to a lack of statistical power, as our 
sample included only 23 obese women with PCOS (data 
not shown).
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Figure 3 Heart rate variability parameters in controls and in women with PCOS at age 46 according to the BMI group. The 
assessment of autonomic function in seated position. The users of beta blockers were excluded. Values are mean±SD or 
median with 25% and 75% quartiles, and the significance testing was made by Student’s t- test (ln- transform was made to 
achieve normality). Statistically significant p values are bolded. HR,heart rate; rMSSD, the root mean square of successive R–R 
differences; LFRRi, low- frequency (0.04–0.15 Hz) power; HFRRi, high- frequency (0.15–0.4 Hz) power; α1, short- term fractal- like 
scaling exponent by detrended fluctuation analysis; SBP, systolic blood pressure; BRS, baroreflex sensitivity; PCOS, polycystic 
ovary syndrome.
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Table 1 Univariate and multivariate linear regression models for heart rate variability measure (rMSSD) in women with PCOS
Variable
Univariate regression analysis
Multivariate model* (B=4.075, 
R2=0.101)
B 95% CI for B P value R2 B 95% CI for B P value
PCOS NA NA NA NA −0.087 −0.190 to 0.016 0.099
BMI 14 years −0.011 −0.022 to 0.000 0.057 0.002
BMI 31 years −0.022 −0.028 to −0.016 <0.001 0.022
BMI 46 years −0.028 −0.033 to −0.023 <0.001 0.055 −0.007 −0.016 to 0.002 0.140
Waist circumference −0.012 −0.014 to −0.010 <0.001 0.061
Systolic BP −0.007 −0.009 to −0.005 <0.001 0.032
Diastolic BP −0.015 −0.017 to −0.013 <0.001 0.066
Mean arterial pressure −0.012 −0.014 to −0.010 <0.001 0.054 −0.007 −0.011 to −0.004 <0.001
Testosterone 0.042 −0.010 to 0.093 0.113 0.001
SHBG 0.001 0.001 to 0.002 <0.001 0.005
FAI −0.121 −0.199 to −0.042 0.003 0.003 0.059 −0.055 to –0.173 0.309
Glucose −0.121 −0.153 to −0.089 <0.001 0.023
Insulin −0.014 −0.018 to −0.011 <0.001 0.027
HOMA- IR −0.492 −0.585 to −0.399 <0.001 0.049 −0.256 −0.420 to −0.092 0.002
Total cholesterol −0.067 −0.096 to −0.038 <0.001 0.009
High- density lipoprotein 0.138 0.076 to 0.201 <0.001 0.008
Low- density lipoprotein −0.086 −0.114 to −0.058 <0.001 0.015
Triglycerides −0.243 −0.285 to −0.200 <0.001 0.050 −0.341 −0.558 to −0.123 0.002
High- sensitive CRP −0.071 −0.084 to −0.057 <0.001 0.034
Anxiety (HSCL-25) −0.195 −0.274 to −0.117 <0.001 0.010
*The multivariate model included PCOS, BMI, mean arterial pressure, FAI, HOMA- IR and triglycerides as explanatory variables. B, 
unstandardized coefficient from linear regression analysis.
BMI, body mass index; BP, blood pressure; CRP, C- reactive protein; FAI, free androgen index; HOMA- IR, homeostasis model assessment−
insulin resistance; NA, not applicable; PCOS, polycystic ovary syndrome; rMSSD, the square root of the mean squared differences of 
successive normal- to- normal RR intervals (RRi); SHBG, sex hormone binding globulin.
linear regression analysis for rMSSD
The univariate linear regression analysis demonstrated 
that rMSSD was associated with BMI at ages 31 and 46 
and with waist circumference, anxiety, SBP, DBP, MAP 
and the serum levels of total cholesterol, HDL, LDL, 
triglycerides, glucose, insulin, HOMA- IR, SHBG, FAI and 
hsCRP at age 46 (table 1). The BMI at age 14 was not 
associated with rMSSD. The multivariate linear regres-
sion analysis demonstrated that MAP, HOMA- IR and 
triglycerides were the strongest explanatory variables for 
rMSSD (table 1).
hyperandrogenaemia
Total or calculated free T at age 46 did not associate 
with rMSSD in the linear regression analysis (data not 
shown). The FAI was negatively associated with rMSSD 
(B=−0.121, 95% CI: −0.199 to −0.042, p=0.003), but lost 
its significance after an adjustment for BMI. Similarly, the 
serum level of SHBG was positively associated with rMSSD 
(B=0.001, 95% CI: 0.001 to 0.002, p<0.001), but lost its 
significance after a BMI adjustment.
DISCuSSIOn
To our knowledge, this is the first study to investigate 
the cardiac autonomic function of late reproductive 
age women with PCOS. We demonstrate here, in a large 
general population- based setup, that late reproductive 
aged women with PCOS display reduced HRV, indicating 
reduced parasympathetic activity. However, in the multi-
variate linear regression analysis, the reduced HRV was 
associated with elevated BP, insulin resistance and dyslip-
idaemia, but not PCOS per se, demonstrating that meta-
bolic abnormalities are likely to be the main cause for 
reduced HRV in women with PCOS.
Previous studies have reported that women with 
PCOS display impaired cardiac autonomic function with 
decreased parasympathetic and increased sympathetic 
activity.10–12 In line with our findings, a study of 75 over-
weight women with PCOS and 75 age and BMI- matched 
controls suggested that impaired HR recovery, a marker 
for decreased parasympathetic activity, was caused by 
excess weight and insulin resistance and not by PCOS 
per se.30 Furthermore, a cross- sectional study of 31 PCOS 
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cases recruited from outpatient clinics reported that 
women with PCOS showed significantly decreased vagal 
activity, but the role of confounding metabolic abnormal-
ities was not assessed, even though the women with PCOS 
had significantly higher BMIs, waist–hip ratios, BP and 
serum levels of T and glucose than the control women.10 
Our findings are also in line with previous studies 
conducted in the general population in which an associa-
tion between BP, glucose metabolism, dyslipidaemia and 
cardiac autonomic function was reported.5 31
In the present study, the overweight/obese women with 
PCOS had more adverse changes in HRV parameters than 
the overweight/obese control women, whereas the lean 
PCOS and control groups had comparable HRV values. 
However, the difference between the overweight/obese 
PCOS and control groups may have reflected the higher 
mean BMIs and waist circumferences and the higher 
prevalence of abnormal glucose metabolism in the over-
weight/obese PCOS group than in the overweight/obese 
controls. Previous studies have reported conflicting results 
regarding the effect of BMI on autonomic function in 
PCOS. A study of 19 overweight/obese women with PCOS 
and 21 overweight/obese control women reported that 
the women with PCOS had elevated muscle sympathetic 
nervous activity (MSNA), whereas HRV parameters did not 
significantly differ between the groups.13 However, it was 
reported that the non- obese (BMI <30 kg/m2) control and 
PCOS groups did not have significantly different SD of all 
RRis (SDNN), rMSSD or percentage of successive differ-
ences in RRi >50 ms (pNN50), whereas the obese (BMI 
≥30 kg/m2) women with PCOS had significantly decreased 
SDNN and pNN50, but not rMSSD.32 The findings of that 
study also demonstrated that sympathetic skin responses, 
investigated by electromyography from the median or tibial 
nerve, were altered in both the non- obese and obese PCOS 
groups. These conflicting results might be explained by 
the fact that the effect of obesity in sympathetic activation 
might be regional, as obesity has been reported to increase 
sympathetic activity in the kidneys and skeletal muscle 
vasculature but to reduce it in the heart.33
We found that serum T or FAI at age 46 did not asso-
ciate with HRV after BMI adjustment (nor did FAI or 
T at age 31, data not shown). In line with our find-
ings, two previous studies found no significant associ-
ation between T and LF12 or hormonal profile and HR 
recovery.11 By contrast, the total T level was reported 
to be inversely associated with LF and LF/HF ratio in 
the women with PCOS during mental stress testing.34 
However, in the present study, we used the golden stan-
dard, a liquid- tandem mass- spectrometry assay for T 
measurement, whereas the previous studies have used 
immunoassays.11 34 Another study found higher MSNA 
in the normal weight women with PCOS compared with 
the normal weight controls, and the strongest explana-
tory factors for higher MSNA in the women with PCOS 
were total and free T and cholesterol.14 However, MSNA 
describes sympathetic activity, whereas HRV mainly 
describes parasympathetic activity.
Also, the phenotype of PCOS was suggested to influ-
ence cardiac autonomic function, as the anovulatory 
women with PCOS showed lower HRV response in mental 
stress tests than the controls, whereas the ovulatory PCOS 
women showed intermediate values.34 However, in that 
study, the women with anovulatory PCOS had a different 
metabolic profile than those with ovulatory PCOS and 
the control groups.34 Furthermore, previous studies have 
indicated that anxiety was associated with reduced HRV 
in the general population.8 In our analysis, anxiety had 
a weak association with rMSSD in the univariate linear 
regression model, although a further analysis revealed 
that metabolic abnormalities played a more important 
role in the reduction of vagal activity.
A recent study addressed the inter- related effects of 
insulin resistance, hyperandrogenism, chronic inflamma-
tion and sympathetic dysfunction (evaluated by MSNA) 
in 49 PCOS and 23 control women; based on the find-
ings, the authors concluded that sympathetic dysfunction 
and hyperandrogenism were associated with PCOS and 
that chronic inflammation might be the mediating factor 
between sympathetic function, hyperandrogenism and 
insulin resistance.35 However, in the present study, the 
surrogate marker of sympathetic activity, LFSBP, did not 
significantly differ between the PCOS and control women, 
suggesting that in our population the women with PCOS 
would not have increased sympathetic activity. This needs 
to be interpreted with caution as LFSBP does not directly 
measure sympathetic activity. The frequency width of 
0.04–0.15 Hz used in the present study could be consid-
ered a limitation, as a frequency width of 0.075–0.15 Hz 
is affected by sympathetic modulation.36 However, the LF 
oscillation of BP usually has a central frequency at ~0.1 Hz 
which considerably varies in relation to sympathetic 
effect,37 38 supporting the use of a wider spectral band for 
LFSBP. Of note, in our data, the women with PCOS had 
significantly lower BRS, but the significance disappeared 
after adjusting for BMI, indicating that PCOS per se does 
not affect BRS.
The strength of our study is that it includes by far 
the largest sample size of women with PCOS and HRV 
measurements. The data also add to the literature by 
representing a community- based approach. Moreover, 
we were able to adjust for many confounding factors 
and to study the effect of metabolic abnormalities. Also, 
this is the first study to investigate women with PCOS at 
a late fertile age. The definition of the PCOS popula-
tion could be considered a limitation; however, we have 
previously shown that the population does display the 
typical endocrine, metabolic and psychological profiles 
of PCOS.21–23 Moreover, a recent genome- wide meta- 
analysis reported that the genetic architecture does not 
differ based on the diagnostic criteria used for PCOS 
(self- reported, NIH criteria or non- NIH Rotterdam 
criteria),39 thus supporting our approach. Our study 
population included only women with Caucasian 
ethnicity; consequently, our results are best generalised 
to PCOS women with Caucasian ethnicity, as ethnicity 
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is known to affect many traits of PCOS. In addition, a 
longer HRV recording period would have been more 
favourable, but due to logistical reasons and the large 
number of subjects to measure we had to limit the time. 
However, the recording period of 150 s used in the 
present study should be reliable.15
In conclusion, in this community- based data set, the 
women with PCOS displayed reduced vagal activity at 
a late fertile age with a strong association with meta-
bolic abnormalities. The fact is that impaired cardiovas-
cular autonomic function (ie, increased sympathetic/
decreased parasympathetic activity) reflects the risk 
for cardiac morbidity; also this is most likely the case 
in PCOS. This underlines the importance of the active 
screening and treatment of metabolic abnormalities 
in women with PCOS, as also suggested by the recently 
published guidelines for PCOS.40 Previous studies have 
reported that in overweight/obese women with PCOS, 
the impaired cardiovascular autonomic function could 
be improved by a 10- week energy restriction,41 a 3- month 
aerobic exercise training programme42 or acupuncture.43 
Importantly, it has been shown that the autonomic distur-
bance can be reversed with weight reduction,44 which 
should justify increasing resources and efforts targeting 
weight management.
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